Sygen Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 120

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 3

Sygen General Information

Description

Manufacturer of pharmaceutical drugs intended to make drugs affordable, available, and easily accessible to the middle and lower-income demographic of the economy. The company's product line covers analgesic, anti-diabetics, antifungal, anti-spasmodic, cough medications, and hematinic drug segments, enabling customers to live a healthy life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Lagos
  • Nigeria
+234 0906
Primary Industry
Pharmaceuticals
Vertical(s)
LOHAS & Wellness
Corporate Office
  • Lagos
  • Nigeria
+234 0906

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sygen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 01-Mar-2023 Completed Generating Revenue
1. Early Stage VC 20-Jan-2021 Completed Generating Revenue
To view Sygen’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Sygen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sygen Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Argentil Capital Partners Growth/Expansion Minority
Healthcap Africa Venture Capital Minority
Argentil Capital Management PE/Buyout Minority
To view Sygen’s complete investors history, request access »

Sygen Investments & Acquisitions (2)

Sygen’s most recent deal was a Joint Venture with Sygen-ORx Biosciences. The deal was made on 16-Aug-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sygen-ORx Biosciences 16-Aug-2024 Joint Venture Drug Discovery
Nigerian German Chemicals 14-Feb-2020 Merger/Acquisition Multi-line Chemicals
To view Sygen’s complete investments and acquisitions history, request access »

Sygen FAQs

  • When was Sygen founded?

    Sygen was founded in 2019.

  • Where is Sygen headquartered?

    Sygen is headquartered in Lagos, Nigeria.

  • What is the size of Sygen?

    Sygen has 120 total employees.

  • What industry is Sygen in?

    Sygen’s primary industry is Pharmaceuticals.

  • Is Sygen a private or public company?

    Sygen is a Private company.

  • What is Sygen’s current revenue?

    The current revenue for Sygen is .

  • Who are Sygen’s investors?

    Argentil Capital Partners, Healthcap Africa, and Argentil Capital Management have invested in Sygen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »